Mazdutide Protocol
Dosing & Research
Last Updated: April 22, 2026
Obesity and diabetes trials, GLP-1/glucagon dual-agonist pharmacology, Weight-loss research, NAFLD/metabolic disease studies
Half-Life
Long-acting; roughly supports once-weekly dosing
Administration
Subcutaneous
Frequency
Once Weekly, Same Day Each Week
How It Works
- Obesity and diabetes trials
- GLP-1/glucagon dual-agonist pharmacology
- Weight-loss research
- NAFLD/metabolic disease studies
Dosing Structure
Dose
1-6mg weekly (titrated)
Frequency
Once Weekly, Same Day Each Week
Notes
Starting dose: 1-2mg once weekly. Escalation: Gradual increase over 4-8 weeks. Target dose: 3-6mg once weekly. Titration: Week 1-4: 1-2mg | Week 5-8: 2-3mg | Week 9-12: 3-4mg | Week 13+: up to 6mg based on response and tolerance. No need to increase dose if experiencing benefits. Inject: Abdomen, thigh, or upper arm (rotate). Medical supervision required.
Example Protocols
Dose: 1-6mg weekly (titrated)
Frequency: Once Weekly, Same Day Each Week
Duration: 12-24 weeks; reassess monthly
Off Period: Not listed
Protocol Notes
•
Starting dose: 1-2mg once weekly.
•
Escalation: Gradual increase over 4-8 weeks.
•
Target dose: 3-6mg once weekly.
Titration
Week 1-4: 1-2mgWeek 5-8: 2-3mgWeek 9-12: 3-4mgWeek 13+: up to 6mg based on response and tolerance
•
No need to increase dose if experiencing benefits.
•
Inject: Abdomen, thigh, or upper arm (rotate).
•
Medical supervision required.
Research & Studies
Loading citations…
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.